Background: Therapy-related acute myeloid leukemia (t-AML) is defined as AML that develops after exposure to cytotoxic chemotherapy and/or radiation therapy. There is a paucity of available literature, particularly in regard to t-AML following childhood cancer. Our aim was to describe the risk of t-AML among children treated for other cancers and their subsequent survival.
INTRODUCTION
Therapy-related acute myeloid leukemia (t-AML) is a recognized diagnosis in which AML develops in a patient previously exposed to chemotherapy and/or radiotherapy. 1 In most cases, it follows the treatment of a primary malignancy or, less frequently, an autoimmune condition.
t-AML is a rare disease and has been estimated to account for approximately 10% of all AML diagnoses among adults. 2 It is also well established that t-AML has a poor prognosis. 3 Patients with a diagnosis Abbreviations: ACCR, Australian Childhood Cancer Registry; CI, confidence interval; HSCT, hematopoietic stem cell transplantation; SIR, standardized incidence ratio; t-AML, therapy-related acute myeloid leukemia. of t-AML are known to experience significantly inferior survival than those diagnosed with de novo AML among both adults 4, 5 and children. 6 Not only is prognosis worse for patients diagnosed with t-AML but it appears that they are also more susceptible to toxicities associated with treatment. In patients with a history of prior chemotherapy use or radiotherapy exposure, tolerability to further treatment is reduced.
Kayser et al. 5 found that in more intensely treated younger adults, treatment-related toxicity had a major negative impact on outcome and proposed that this may reflect the cumulative toxicity of cancer treatment.
Prior use of alkylating agents, radiation therapy, and/or topoisomerase II inhibitors appears to carry the greatest risk for development of t-AML. 7 t-AML occurring after the use of these agents is associated with certain chromosomal and cytogenetic abnormalities not as commonly seen in de novo AML. Such abnormalities seem to confer adverse risk and increased likelihood of relapse. 8 The latency period between the primary diagnosis requiring chemotherapy and/or radiotherapy and the development of t-AML varies considerably from a few months to many years. Risk for development of t-AML and the latency period both appear to be associated with the type of chemotherapeutic agent used, the timing of exposure, and the dose of the agent used. 9 Due to the rarity of t-AML diagnoses following childhood cancer, much remains to be studied in terms of patient cohort characteristics and prognosis. Our study aimed to utilize a national, population-based dataset to describe the risk of t-AML among a cohort treated for other childhood cancers and their subsequent survival.
METHODS

Data
A retrospective analysis was conducted of de-identified longitudinal data from the Australian Childhood Cancer Registry (ACCR). Information on all notified cases of cancer for children aged 0 to 14 at diagnosis is collected from population cancer registries in each Australian State and Territory under appropriate ethics and legislative approvals. Cancer type was defined according to the International Classification of Childhood Cancers, third edition (ICCC-3). 10 Cases held by the ACCR are matched annually against the Australian Cancer Database and the National Death Index to ensure that all subsequent cancers diagnosed at any age are recorded in the ACCR database and that mortality status is updated. Treatment details are also collected by the ACCR for all cancers diagnosed before 15 years of age.
The study cohort included children (aged <15 years) who were diagnosed with a first primary cancer (other than AML) during the period 1983-2012 and treated with chemotherapy and/or radiotherapy. Exclusion criteria were a first diagnosis of AML, the first primary malignancy was diagnosed prior to 1983, if the patient was from overseas but treated in Australia, or if the start date of treatment was not recorded.
Unique registry numbers were used to match first and second cancers for the same patient, with follow-up available up to December 31, 2014. Any AML that was subsequently diagnosed within this cohort was taken to be t-AML, that is, a morphology code of AML (ICD-O-3   codes 9840, 9861, 9866, 9867, 9870-9874, 9891, 9895-9897, 9910, 9920, or 9931) any time after the initiation of chemotherapy or radiation for the first primary cancer.
Analysis
For each patient with childhood cancer who received chemotherapy or radiotherapy, their time at risk (follow-up) was calculated from the date of first treatment until either the end of the study period (December 31, 2014), date of death, or date of diagnosis of t-AML, whichever came first. The maximum possible age at diagnosis for t-AML was 46 years (for a 14-year-old diagnosed with a first cancer during 1983 and diagnosed with t-AML in 2014).
Given that an open-ended followup period may be expected to somewhat dilute the results, analyses were also performed with follow-up arbitrarily finishing at the patient's 25th birthday for comparison. Age-adjusted incidence rates of t-AML were calculated, using the time at risk as the denominator and standardized to the 2000 World Standard Population.
Standardized incidence ratios (SIRs) were used to approximate the risk of developing t-AML following treatment with either chemotherapy or radiotherapy, relative to the incidence of AML within the general population. The expected number of second primary cancers was calculated by multiplying the time at risk (in years) by the incidence rate of AML experienced by the general population in Australia, matched by sex, 5-year age group, and calendar year. Incidence rates were averaged over blocks of 4 calendar years to produce more stable estimates.
SIRs were then obtained by dividing the observed number of t-AML cases by the expected number. The cumulative incidence function for t-AML was also calculated, with any death considered as a competing risk.
Five-year observed survival was calculated from the date of diagnosis of t-AML using the Kaplan-Meier method. Survival time was censored at either December 31, 2014 or 5 years from the date of t-AML diagnosis (whichever occurred first) for patients who remained alive at those time points. Minimum follow-up from the date of diagnosis of t-AML for a patient who was still alive as of December 31, 2014 was 7 months. Relapse was not considered as a competing event. Differences in unadjusted survival by key variables of interest were assessed using the log-rank test.
Point estimates for SIRs and survival, along with 95% confidence intervals (CIs), were calculated for key demographic and clinical variables of interest including sex, age group, time period of diagnosis, broad type of first cancer, and treatment received. Note that treatment details for t-AML were only collected in the ACCR for patients diagnosed with t-AML before 15 years of age. All data analysis was performed using Stata SE for Windows v15 software. Specific ethics approvals were not required for this study as it was conducted using de-identified data only. Of the 11,753 eligible patients, 58 (0.5%) were diagnosed with t-AML by December 31, 2014. The age-standardized incidence rate of t-AML among those at risk was 24.1 per 100,000 person years (95% CI = 18.1-31.5). Most t-AML cases (n = 45, 78%) were diagnosed within 5 years of the first primary cancer, with a median time between the commencement of treatment for the first cancer to diagnosis of t-AML of only 2.4 years (interquartile range = 1.9-4.6 years). Although followup was available up to a maximum age of 46 years for some patients, no cases of t-AML were diagnosed after the age of 24, emphasizing that t-AML was most likely to occur relatively soon after treatment for the original cancer. Truncating follow-up at each patient's 25th birthday gave an age-standardized incidence rate of 44.0 per 100,000 person years (95% CI = 32.9-57.4).
RESULTS
Study cohort
Only eight out of the 58 t-AML cases (14%) had a morphology code of M99203 (therapy-related AML). The most common morphology given in the pathology reports was M98613 (acute myeloid leukemia not otherwise specified) with 25 cases (43%), followed by 10 cases (22%) which were coded as M98913 (acute monocytic leukemia).
Incidence distribution and relative risk of t-AML
Patients with childhood cancer treated with chemotherapy and/or radiotherapy had a greatly increased risk of subsequently being diagnosed with AML (SIR = 45.6, 95% CI = 35.3-59.0) compared to the general population (Table 1) . If follow-up time was capped at each person's 25th birthday, the SIR rose to 56.0 (95% CI = 43.3-72.5). Twenty-year cumulative incidence was 0.7% (95% CI = 0.5-1.0%).
The number of males diagnosed with t-AML (n = 39, 67% of t-AML diagnoses) was around double the number of females (n = 19) (Table 1) .
However, despite the suggestion that males were at an increased relative risk of developing t-AML following childhood cancer compared to females, with SIRs of 52.7 and 35.7, respectively, the small number of cases available meant that the resulting SIR ratio of 1.48 for males to females was not statistically significant (95% CI = 0.83-2.70; P = 0.20).
Approximately half (47%) of those in the cohort who developed t-AML were aged 0-4 years at the time of their first cancer diagnosis, consistent with the median age of 5 years for all childhood cancers.
The type of first cancer was evenly divided between blood cancers (excluding AML) and solid tumors. More specifically, the most common original cancers were acute lymphoid leukemia (n = 21, 36%), Ewing bone tumors, and rhabdomyosarcoma (both n = 6, 10%). There was no clear evidence of any difference in the relative risk of t-AML depending on the broad type of the first cancer, with the SIR ratio for blood cancers (excluding AML) to solid tumors being 0.79 (95% CI = 0.46-1.37, P = 0.44).
Treatment
As shown in Table 1 , nearly all (n = 57, 98%) patients who were diagnosed with t-AML received chemotherapy for their first cancer, 20 (34%) were also treated with radiotherapy, and seven (12%) underwent hematopoietic stem cell transplantation (HSCT) using bone marrow or peripheral stem cells. Of note, the SIR for t-AML among children following HSCT for their first cancer was more than double that of the study cohort in general, at 120.7 (95% CI = 57.5-253.2).
Treatment details for t-AML were also available for the 44 children who were diagnosed with t-AML prior to reaching 15 years of age. Of these patients, 33 (75%) received chemotherapy coupled with either were not given HSCT (P < 0.001).
Survival
Almost three-quarters of the cohort (41 out of 58, 71%) had died by the end of the study period (December 31, 2014). The majority of these deaths (n = 38, 93%) occurred within 2 years of t-AML diagnosis. Fiveyear observed survival was 31% (95% CI = 19.6-43.5%) from the time of t-AML diagnosis (Figure 1 ).
No significant disparities in survival following t-AML were recorded by sex, age at t-AML diagnosis, time from first diagnosis to t-AML diagnosis, year of t-AML diagnosis, or type of first cancer ( Table 2 , Figure 2 ), although this appeared to be partly due to the small number of cases available. For example, 5-year observed survival was more than double for females compared to that for males (50% vs. 23%), but the difference failed to reach statistical significance (P = 0.08).
Both chemotherapy and HSCT following t-AML were, however, associated with a survival advantage among those patients for whom this information was available (i.e., diagnosed with t-AML before 15 years of age). Of particular interest, 5-year observed survival was 52% for the group who had HSCT in contrast to 6% for children who did not receive HSCT to treat t-AML (P < 0.001). All of the 14 children aged under 15 who did not achieve remission following t-AML died within 2 years of diagnosis (Table 2) .
DISCUSSION
Using a population-based cohort, we provide here the first description of the relative risk of t-AML being diagnosed following treatment for childhood cancer; to the best of our knowledge, this information has never been previously reported in either a pediatric or adult setting.
Although the absolute risk was small, our finding that survivors who were treated with chemotherapy and/or radiotherapy had an almost 50-fold increased risk compared to those without cancer helps to quantify the impact that childhood cancer can have beyond the initial diagnosis. This is especially pertinent given that AML is one of the most commonly diagnosed malignancies among childhood cancer survivors, accounting for 17% of all second primary cancers in Australia. 11 While caution is needed when interpreting results based on a small number of cases, our finding that males comprise two-thirds of t-AML cases following childhood cancer is worth some consideration, particularly when paired with the suggestions (although not statistically significant) that males may also be at higher relative risk and have a worse prognosis than females. Comparable distributions by sex have been reported among pediatric patients with t-AML in the United States 6 and Japan. 12 Interestingly, this is in direct contrast to results seen in adult studies on t-AML which show a clear female predominance. 13, 14 A Swedish study 14 assumed that the female excess seen in the number of adult t-AML cases was a by-product of the fact that breast cancer was the most prevalent cancer in that population, thereby allowing a greater opportunity for t-AML to develop among females. Similarly, the excess of young males with t-AML may be at least partly accounted for by childhood cancer being somewhat more common among males than among females (55% vs. 45% in Australia) 11 ; even so, this does explain why t-AML appears to pose more of a risk among male survivors of pediatric cancer. Further investigation in other populations is warranted.
The current study aligns with information provided on adult cohorts, which show that t-AML arises in equal proportions following primary hematological malignancies and primary solid tumors. 8 Half of the patients with childhood cancer developed t-AML between 2 and 5 years after the first diagnosis, which is also in keeping with prior adult studies that found a median latency period of 4-5 years. 15 A few studies conducted using surveys of hospital-based series of pediatric patients have reported outcomes for t-AML, 6, 12, [16] [17] [18] [19] but some of the findings are difficult to interpret as t-AML tends to be mixed in with other therapy-related cancers. Further, each of these studies involved a very small number of patients with t-AML (range of 16-36). 18, 19 Our findings, examining how survival varies by key patient and clinical characteristics using the largest cohort of childhood cancer survivors diagnosed with t-AML that have been studied to date, therefore add valuable information to the limited existing literature.
In particular, the current study substantiates the poor prognosis associated with a diagnosis of t-AML following childhood cancer;
5-year observed survival for t-AML was 31% compared to a recent estimate of 77% for 5-year relative survival following all childhood AML in Australia. 20 We were also able to verify a striking 5-year survival benefit when HSCT was used to treat t-AML. Our results are consistent with studies elsewhere 6, 12, [16] [17] [18] that have demonstrated the therapeutic benefits of HSCT for pediatric patients with t-AML. These collective findings indicate that therapy for t-AML in children should be with the aim of achieving remission and bridging patients to HSCT. Given the high mortality associated with t-AML and with our study identifying HSCT as an effective therapy, it seems prudent that children should be prepared for HSCT as soon as possible after a diagnosis of t-AML to increase their chance of survival. Some authors 17, 19 do, however, warn of high rates of nonrelapse mortality following transplant. It is important to acknowledge that we are unable to rule out potential confounding factors associated with the use of HSCT. Perhaps the most notable is our inability to report on why certain pediatric patients were offered HSCT and others where not. For example, if the reason patients were not offered HSCT was because they were too unwell or that they died before it was possible to perform the procedure, then our finding may simply represent their pre-existing poor condition rather than the effectiveness of HSCT as a therapy for t-AML. Furthermore, it has been shown that outcomes following HSCT in AML are inferior when performed in the setting of refractory disease, particularly for children aged over 10 years with >30% blasts in the bone marrow, 21 so it is likely that patients failing to achieve remission after initial chemotherapy were either not offered or declined HSCT. Our results should also be interpreted with the understanding that HSCT is continually being refined, 22 with studies demonstrating a clear trend towards a reduction in transplant-related mortality over time. [23] [24] [25] As such, it is likely that success rates will continue to increase into the future and so the current survival benefit of HSCT may actually be greater than what we report here over the previous three decades.
TA B L E 2
Unfortunately, we were unable to investigate whether survival rates for HSCT have improved over time as there was an insufficient number of cases to stratify survival following HSCT by the period of t-AML diagnosis.
A strength of our study is that the ACCR is population-based, allowing us to draw conclusions at a national level. Using data from the ACCR also allowed us the benefit of having a longitudinal approach over a 30-year period. This meant we were able to report on the temporal relationship between primary cancer diagnosis, t-AML diagnosis, and 5-year survival outcomes.
Use of morphology code M99203 (therapy-related AML) is recommended for accurate identification of patients with t-AML. One potential limitation of our study is that very few patients had the F I G U R E 2 Kaplan-Meier observed survival curves for t-AML following childhood cancer in Australia, 1982-2014 by (A) sex; (B) age at t-AML diagnosis; (C) time period of t-AML diagnosis; (D) type of first cancer; (E) chemotherapy following t-AML diagnosis, and (F) HSCT treatment following t-AML diagnosis. P-values for equality of survivor functions were calculated using the log-rank test. Solid tumors include initial cases of medulloblastoma, primitive neuroectodermal tumor, neuroblastoma, nephroblastoma, hepatic carcinoma, osteosarcoma, Ewing tumor, unspecified malignant bone tumor, rhabdomyosarcoma, nonrhabdomyosarcoma soft tissue sarcoma, and intracranial and intraspinal germ cell tumors. Treatment received for t-AML was only available for the 44 children who were diagnosed with t-AML before 15 years of age appropriate morphology code and instead we had to make the reasonable assumption that any diagnosis of AML following treatment with chemotherapy and/or radiotherapy constituted t-AML. We, therefore, cannot rule out that some cases of pediatric t-AML may have been either missed or misidentified. Imprecision in coding is likely to hinder research into t-AML when relying on cancer registry data, as comprehensive treatment data are often lacking.
Similarly, it is recognized that t-AML can occur after nonmalignant primary diagnoses that also require chemotherapy or radiotherapy as treatment, particularly autoimmune conditions. 26 The ACCR is a cancer database only and as such other primary diseases are not recorded.
We may therefore be missing a small number of patients who developed t-AML after treatment for a nonmalignant condition and these children may have different characteristics and associated prognosis.
Finally, the statistical power of our analysis has been restricted by the small number of t-AML cases available for study, making it difficult to detect differences in SIRs and survival estimates when stratified by key variables of interest. It was also not feasible to apply multivariate models to the data to calculate adjusted survival for this reason.
In conclusion, t-AML is a rare disease with relatively short latency from a prior cancer diagnosis. Although the prognosis is poor for most patients, our results indicate that a significant number can be salvaged with HSCT. Advances in HSCT techniques that increase donor options, such as haploidentical transplantation, may improve outcomes for those who respond to induction therapy and can undergo the procedure.
